Christoph Denk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christoph Denk has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Hannes Mikula
TU Wien
7 shared publications - Dennis Svatunek
Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
5 shared publications - Claudia Kuntner
Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
3 shared publications Thomas Filip
Health and Environment Department, Biomedical Systems, Austrian Institute of Technology (AIT), Seibersdorf, Austria
3 shared publications- Thomas Wanek
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
3 shared publications - Andreas Kjaer
Rigshospitalet
2 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 54 (42) , 15701-15704
Fast and easy reactor-based production of copper-64 with high molar activities using recoil chemistry
We identified tert -butyl copper( ii ) phthalocyanine as the target material for reactor-based production of medically relevant quality and quantity copper-64 using recoil chemistry.
- 21 October 2025
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 54 (42) , 15701-15704
Open AccessFast and easy reactor-based production of copper-64 with high molar activities using recoil chemistry
We identified tert -butyl copper( ii ) phthalocyanine as the target material for reactor-based production of medically relevant quality and quantity copper-64 using recoil chemistry.
- Open Access
- 1 March 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 320
Towards DFO*12—Preliminary Results of a New Chelator for the Complexation of Actinium-225
Background: Actinium-225 (225Ac) has gained interest in nuclear medicine for use in targeted alpha therapy (TAT) for the treatment of cancer. However, the number of suitable chelators for the stable complexation of 225Ac3+ is limited. The promising physical properties of 225Ac result in an increased demand for the radioisotope that is not matched by its current supply. To expand the possibilities for the development of 225Ac-based TAT therapeutics, a new hydroxamate-based chelator, DFO*12, is described. We report the DFT-guided design of dodecadentate DFO*12 and an efficient and convenient automated solid-phase synthesis for its preparation. To address the limited availability of 225Ac, a small-scale 229Th/225Ac generator was constructed in-house to provide [225Ac]AcCl3 for research. Methods: DFT calculations were performed in ORCA 5.0.1 using the BP86 functional with empirical dispersion correction D3 and Becke–Johnson damping (D3BJ). The monomer synthesis over three steps enabled the solid-phase synthesis of DFO*12. The small-scale 229Th/225Ac generator was realized by extracting 229Th from aged 233U material. Radiolabeling of DFO*12 with 225Ac was performed in 1 M TRIS pH 8.5 or 1.5 M NaOAc pH 4.5 for 30 min at 37 °C. Results: DFT calculations directed the design of a dodecadentate chelator. The automated synthesis of the chelator DFO*12 and the development of a small-scale 229Th/225Ac generator allowed for the radiolabeling of DFO*12 with 225Ac quantitatively at 37 °C within 30 min. The complex [225Ac]Ac-DFO*12 indicated good stability in different media for 20 h. Conclusions: The novel hydroxamate-based dodecadentate chelator DFO*12, together with the developed 229Th/225Ac generator, provide new opportunities for 225Ac research for future radiopharmaceutical development and applications in TAT.
- 1 March 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 320
Open AccessTowards DFO*12—Preliminary Results of a New Chelator for the Complexation of Actinium-225
Background: Actinium-225 (225Ac) has gained interest in nuclear medicine for use in targeted alpha therapy (TAT) for the treatment of cancer. However, the number of suitable chelators for the stable complexation of 225Ac3+ is limited. The promising physical properties of 225Ac result in an increased demand for the radioisotope that is not matched by its current supply. To expand the possibilities for the development of 225Ac-based TAT therapeutics, a new hydroxamate-based chelator, DFO*12, is described. We report the DFT-guided design of dodecadentate DFO*12 and an efficient and convenient automated solid-phase synthesis for its preparation. To address the limited availability of 225Ac, a small-scale 229Th/225Ac generator was constructed in-house to provide [225Ac]AcCl3 for research. Methods: DFT calculations were performed in ORCA 5.0.1 using the BP86 functional with empirical dispersion correction D3 and Becke–Johnson damping (D3BJ). The monomer synthesis over three steps enabled the solid-phase synthesis of DFO*12. The small-scale 229Th/225Ac generator was realized by extracting 229Th from aged 233U material. Radiolabeling of DFO*12 with 225Ac was performed in 1 M TRIS pH 8.5 or 1.5 M NaOAc pH 4.5 for 30 min at 37 °C. Results: DFT calculations directed the design of a dodecadentate chelator. The automated synthesis of the chelator DFO*12 and the development of a small-scale 229Th/225Ac generator allowed for the radiolabeling of DFO*12 with 225Ac quantitatively at 37 °C within 30 min. The complex [225Ac]Ac-DFO*12 indicated good stability in different media for 20 h. Conclusions: The novel hydroxamate-based dodecadentate chelator DFO*12, together with the developed 229Th/225Ac generator, provide new opportunities for 225Ac research for future radiopharmaceutical development and applications in TAT.
- Open Access
- 4 March 2024
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 53 (13) , 6031-6040
Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.
- 4 March 2024
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 53 (13) , 6031-6040
Open AccessSynthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.
- Open Access
- 15 November 2023
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 154 (12) , 1441-1457
Post-radiolabeling thioether oxidation to enhance the bioorthogonal reactivity of 18F-tetrazines
Radiolabeled 1,2,4,5-tetrazines are powerful heterocyclic agents for bioorthogonal PET imaging due to their fast cycloaddition with trans-cyclooctenes. However, fluorine-18 radiolabeling of highly reactive tetrazines is often not feasible due to limited compound stability. We demonstrate that post-radiolabeling oxidation of thioether functionalities is a viable and transferable strategy to avoid these limitations, enabling the synthesis of highly reactive 18F-tetrazines. Graphical abstract
- 15 November 2023
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 154 (12) , 1441-1457
Open AccessPost-radiolabeling thioether oxidation to enhance the bioorthogonal reactivity of 18F-tetrazines
Radiolabeled 1,2,4,5-tetrazines are powerful heterocyclic agents for bioorthogonal PET imaging due to their fast cycloaddition with trans-cyclooctenes. However, fluorine-18 radiolabeling of highly reactive tetrazines is often not feasible due to limited compound stability. We demonstrate that post-radiolabeling oxidation of thioether functionalities is a viable and transferable strategy to avoid these limitations, enabling the synthesis of highly reactive 18F-tetrazines. Graphical abstract
- 1 September 2021
- Published by Elsevier in World Neurosurgery
- Vol. 153, e244-e249
Clinical Outcome and Technical Nuances After Resection of Orbital Cavernous Venous Malformations—A Single-Center Experience
- 1 September 2021
- Published by Elsevier in World Neurosurgery
- Vol. 153, e244-e249
Clinical Outcome and Technical Nuances After Resection of Orbital Cavernous Venous Malformations—A Single-Center Experience
- Open Access
- 15 February 2019
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2019 (8) , 1686
Cover Feature: Convenient Entry to 18F‐Labeled Amines through the Staudinger Reduction (Eur. J. Org. Chem. 8/2019)
- 15 February 2019
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2019 (8) , 1686
Open AccessCover Feature: Convenient Entry to 18F‐Labeled Amines through the Staudinger Reduction (Eur. J. Org. Chem. 8/2019)
- Open Access
- 17 December 2018
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2019 (8) , 1722-1725
Convenient Entry to 18F‐Labeled Amines through the Staudinger Reduction
Fluorine‐18 possesses outstanding decay characteristics for positron emission tomography (PET) imaging. Therefore, it is ideally suited for clinical applications. As such, improved strategies to incorporate fluorine‐18 into bioactive molecules are of utmost importance. Indirect 18F‐labeling with amino‐functionalized synthons is a convenient and versatile approach to synthesize a broad variety of PET tracers. Herein, we report a method to convert 18F‐labeled azides to primary amines by means of the Staudinger reduction. Aliphatic and aromatic 18F‐labeled azides were converted into the corresponding amines with high conversion yields. The method was easily automated. From a broader perspective, the applied strategy results in two useful synthons from a single precursor and thus increases the flexibility to label diverse chemical scaffolds with minimal synthetic effort.
- 17 December 2018
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2019 (8) , 1722-1725
Open AccessConvenient Entry to 18F‐Labeled Amines through the Staudinger Reduction
Fluorine‐18 possesses outstanding decay characteristics for positron emission tomography (PET) imaging. Therefore, it is ideally suited for clinical applications. As such, improved strategies to incorporate fluorine‐18 into bioactive molecules are of utmost importance. Indirect 18F‐labeling with amino‐functionalized synthons is a convenient and versatile approach to synthesize a broad variety of PET tracers. Herein, we report a method to convert 18F‐labeled azides to primary amines by means of the Staudinger reduction. Aliphatic and aromatic 18F‐labeled azides were converted into the corresponding amines with high conversion yields. The method was easily automated. From a broader perspective, the applied strategy results in two useful synthons from a single precursor and thus increases the flexibility to label diverse chemical scaffolds with minimal synthetic effort.
- Open Access
- 27 June 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (28) , 5976-5982
[18F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry
[18F]Fluoroalkyl azides were developed as efficient click agents for rapid radiolabeling, and (re)investigated towards application in pretargeted PET imaging.
- 27 June 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (28) , 5976-5982
Open Access[18F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry
[18F]Fluoroalkyl azides were developed as efficient click agents for rapid radiolabeling, and (re)investigated towards application in pretargeted PET imaging.
- Open Access
- 7 July 2014
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 53 (36) , 9675
Inside Back Cover: Development of a18F-Labeled Tetrazine with Favorable Pharmacokinetics for Bioorthogonal PET Imaging (Angew. Chem. Int. Ed. 36/2014)
- 7 July 2014
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 53 (36) , 9675
Open AccessInside Back Cover: Development of a18F-Labeled Tetrazine with Favorable Pharmacokinetics for Bioorthogonal PET Imaging (Angew. Chem. Int. Ed. 36/2014)
- Open Access
- 7 July 2014
- Published by Wiley in Angewandte Chemie
- Vol. 126 (36) , 9829
Innenrücktitelbild: Entwicklung eines18F-markierten Tetrazins mit vorteilhaften pharmakokinetischen Eigenschaften für die bioorthogonale Positronenemissionstomographie (Angew. Chem. 36/2014)
- 7 July 2014
- Published by Wiley in Angewandte Chemie
- Vol. 126 (36) , 9829
Open AccessInnenrücktitelbild: Entwicklung eines18F-markierten Tetrazins mit vorteilhaften pharmakokinetischen Eigenschaften für die bioorthogonale Positronenemissionstomographie (Angew. Chem. 36/2014)